GlassScriptPhysician profile
Jocelyn Moll
NPI 1285090902
$3,617.19
in general payments reported to CMS, 2019-2025
28 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,384 · 2022: $707 · 2023: $52.67 · 2024: $20.28 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $899 · Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $899.10 |
| Food and Beverage | $626.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,419.28 | 2021-2025 | Axonics |
| Teleflex LLC | $252.31 | 2021-2022 | |
| Medtronic, INC. | $209.36 | 2021-2022 | |
| Myovant Sciences INC. | $193.14 | 2021-2022 | |
| Allergan, INC. | $192.97 | 2021-2022 | |
| Astellas Pharma US INC | $176.38 | 2021-2022 | |
| Hollister Incorporated | $160.63 | 2021-2022 | |
| Abbvie INC. | $157.96 | 2021-2023 | |
| Urogen Pharma, INC. | $153.39 | 2021-2022 | |
| 180 Medical, INC. | $85.34 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $76.28 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $72.40 | 2021-2022 | |
| Urovant Sciences INC | $53.23 | 2021-2022 | |
| Procept Biorobotics Corporation | $51.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.89 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.86 | 2023 | Orgovyx |
| Pfizer INC. | $36.89 | 2022 | |
| Axonics, INC. | $33.85 | 2021 | |
| Amgen INC. | $28.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.26 | 2022 | |
| Janssen Biotech, INC. | $24.94 | 2021 | |
| Merck Sharp & Dohme LLC | $23.39 | 2021 | |
| Antares Pharma, INC. | $22.49 | 2021 | |
| Coloplast Corp | $20.28 | 2024 | |
| Rochester Medical Corporation | $17.38 | 2022 | |
| Dentsply Ih Ab | $14.59 | 2021 | |
| Dentsply Ih INC. | $14.13 | 2022 | |
| Acerus Pharmaceuticals Corporation | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Moll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.